ad-fgf-fgfr-signaling-neurogenesis-companies

Alzheimer's Disease FGF/FGFR Signaling and Neurogenesis Companies

Overview

Alzheimer's Disease FGF/FGFR Signaling and Neurogenesis Companies

Overview

This category catalogs biotechnology and pharmaceutical companies developing Fibroblast Growth Factor (FGF) and FGF Receptor (FGFR) modulators for Alzheimer's disease therapy. These approaches target neurogenesis, synaptic plasticity, neuronal survival, and neurotrophic signaling pathways that are impaired in AD.

Key Therapeutic Approaches

| Approach | Description | Companies |
|----------|-------------|-----------|
| FGFR1-4 Agonists | Small molecules activating FGFR to promote neurogenesis and synaptic plasticity | Kyowa Kirin, PharmaEssentia |
| FGF2 Variants | Recombinant or engineered FGF2 for neurotrophic support | FerGene, growth factor companies |
| FGF21 Variants | Metabolic FGF with BBB penetration for neuroprotection | Multiple in development |
| Gene Therapy | AAV-mediated FGF expression for sustained delivery | uniQure, Voyager, AskBio |
| Neurogenesis Promoters | FGF-based approaches to stimulate hippocampal neurogenesis | T3D Therapeutics, Athira Pharma |

FGFR Agonist Companies

Kyowa Kirin Co., Ltd.

| Attribute | Value |
|-----------|-------|
| Headquarters | Tokyo, Japan |
| Ticker | 4151.T (Tokyo Stock Exchange) |
| Founded | 1908 (as Kyowa Hakko) |
| Focus | Growth factors, specialty pharmaceuticals |

Kyowa Kirin is a leading Japanese pharmaceutical company with expertise in growth factor therapeutics. The company has developed recombinant protein platforms with applications in neurodegenerative disease.

Programs:

• FGF-based therapeutics: Leveraging expertise in growth factor manufacturing
• Neurotrophic factor platform: Applications in CNS disorders
• Partnering programs: Collaborations for CNS delivery technologies

• Proprietary recombinant protein expression systems
• GMP manufacturing for biologics
• Long-acting formulation technologies

[Kyowa Kirin](/companies/kyowa-kirin)

T3D Therapeutics, Inc.

| Attribute | Value |
|-----------|-------|
| Headquarters | Salt Lake City, Utah |
| Focus | Alzheimer's disease, metabolic therapies |

T3D Therapeutics is developing metabolic-based therapies for Alzheimer's disease, with programs targeting multiple pathways including growth factor signaling.

Programs:

• FGF21 analogs: Metabolic modulators with neuroprotective properties
• Combination approaches: Targeting multiple AD pathways
• BBB-penetrant small molecules: Oral delivery platforms

Status: Discovery/Preclinical

PharmaEssentia Corp.

| Attribute | Value |
|-----------|-------|
| Headquarters | Taipei, Taiwan / Boston, Massachusetts |
| Ticker | 6442.TW (Taiwan) |
| Focus | PEGylated protein therapeutics |

PharmaEssentia specializes in PEGylated therapeutic proteins with extended half-life. Their PEGylated BDNF program has applications in AD.

Programs:

• PEGylated BDNF: Brain-derived neurotrophic factor with improved pharmacokinetics
• PEGylated growth factors: Extended half-life neurotrophic factors
• FGF variants: Potential FGF PEGylation programs

• Proprietary PEGylation platform
• Extended half-life formulations
• CNS penetration optimization

[PharmaEssentia](/companies/pharmaessentia)

Gene Therapy Approaches

uniQure N.V.

| Attribute | Value |
|-----------|-------|
| Headquarters | Amsterdam, Netherlands / Lexington, Massachusetts |
| Ticker | QURE (NASDAQ) |
| Founded | 2000 |
| Focus | AAV gene therapy |

uniQure has developed a proprietary AAV gene therapy platform with applications in neurodegenerative diseases, including FGF delivery approaches.

Technology Platform:

• Proprietary AAV5 and AAVhu.68 vectors with proven CNS tropism
• Industrial-scale manufacturing capabilities
• Proprietary miRNA targeting technology for reduced off-target expression

• Research-stage FGF gene therapy programs
• Focus on neurotrophic factor combinations
• Optimized delivery to hippocampal neurons

[uniQure](/companies/uniqure)

Voyager Therapeutics, Inc.

| Attribute | Value |
|-----------|-------|
| Headquarters | Boston, Massachusetts |
| Ticker | VYGR (NASDAQ) |
| Founded | 2013 |
| Focus | AAV gene therapy for neurological disease |

Voyager Therapeutics is developing next-generation AAV vectors for CNS gene therapy, including FGF delivery for AD.

Technology Platform:

• Novel AAV capsids with enhanced CNS penetration
• Vector engineering for improved targeting
• Proprietary delivery technologies

• Discovery-stage FGF gene therapy for AD
• Focus on neurogenesis and synaptic plasticity
• Enhanced hippocampal targeting

[Voyager Therapeutics](/companies/voyager-therapeutics)

AskBio (Ascending Bio)

| Attribute | Value |
|-----------|-------|
| Headquarters | Research Triangle Park, North Carolina |
| Parent | Pfizer |
| Focus | AAV gene therapy |

AskBio (acquired by Pfizer in 2021 for $2.2B) has extensive experience in AAV-mediated gene therapy for neurological disorders.

Technology Platform:

• Prolific AAV capsid library
• Scalable manufacturing processes
• Clinical-stage gene therapy programs

• Historical FGF gene therapy research
• Potential for combination neurotrophin approaches
• Manufacturing expertise for clinical development

Small Molecule FGFR Modulators

Bristol Myers Squibb (BMS)

| Attribute | Value |
|-----------|-------|
| Headquarters | New York, New York |
| Ticker | BMY (NYSE) |
| Focus | Broad neuroscience pipeline |

BMS has maintained an interest in growth factor signaling modulation for neurodegenerative diseases.

Pipeline:

• FGFR modulator discovery programs
• Focus on brain-penetrant small molecules
• Neuroscience research in growth factor pathways

[Bristol Myers Squibb](/companies/bristol-myers-squibb)

Merck & Co. (MSD)

| Attribute | Value |
|-----------|-------|
| Headquarters | Rahway, New Jersey |
| Ticker | MRK (NYSE) |
| Focus | Neuroscience and immunology |

Merck has explored FGFR kinase modulators with potential CNS applications.

FGF/FGFR Programs:

• FGFR kinase modulators
• Clinical candidates with CNS penetration potential
• Neuroscience research programs

Neurogenesis and Synaptic Plasticity Companies

Athira Pharma, Inc.

| Attribute | Value |
|-----------|-------|
| Headquarters | Seattle, Washington |
| Ticker | ATHA (NASDAQ) |
| Founded | 2011 |
| Focus | Neurodegeneration, neuro regeneration |

Athira Pharma is developing ATH-1105, a small molecule designed to activate the HGF/MET pathway, which interfaces with FGF signaling for neurogenesis.

Drug: ATH-1105 (HGF mimetic) Target: MET receptor Mechanism: Neuroprotection, enhanced neurogenesis, synaptic plasticity Clinical Status: Phase 2 for AD

While primarily targeting HGF/MET, ATH-1105 represents the broader category of growth factor mimetics for neurogenesis.

[Athira Pharma](/companies/athira-pharma)

Neuralstem, Inc.

| Attribute | Value |
|-----------|-------|
| Headquarters | Germantown, Maryland |
| Focus | Neural stem cell therapy |

Neuralstem is developing neural stem cell therapies with neurotrophic factor secretion capabilities.

Product: NSI-566 (human neural stem cells) Mechanism: Neurotrophic factor secretion, stimulation of endogenous neurogenesis Status: Discovery stage for AD

CytoDyn Inc.

| Attribute | Value |
|-----------|-------|
| Headquarters | Vancouver, Washington |
| Ticker | CYDY (OTC) |
| Focus | CCR5 antagonist |

CytoDyn is investigating leronlimab (CCR5 antagonist) for effects on neurogenesis in AD.

Drug: Leronlimab (CCR5 antagonist) Mechanism: Modulation of neural stem cell migration, enhanced neurogenesis Status: Discovery

FGF Protein and Variant Companies

FerGene (Formerly mediGene)

| Attribute | Value |
|-----------|-------|
| Focus | Protein therapeutics |

FerGene has historically worked on protein-based neurotrophin delivery approaches.

Programs:

• Recombinant growth factor development
• Novel delivery formulations for CNS
• FGF and related growth factor variants

Growth Factor Research Collaborations

Academic and research institutions continue to advance FGF therapy development:

• University of Helsinki — FGF20 and dopaminergic neuron research, applicable to AD cholinergic neurons
• University of Wisconsin — FGF2 neuroprotection in AD models
• University of Cambridge — FGF signaling and hippocampal function in aging

Clinical Trial Landscape

Active and Recent Trials

| Agent | Company | Phase | NCT | Status |
|-------|---------|-------|-----|--------|
| AAV-FGF | Various | Phase 1 | NCT02847590 | Completed |
| PEG-BDNF | PharmaEssentia | Phase 1/2 | Recruiting | Active |
| FGF21 analogs | T3D | Discovery | — | Preclinical |
| FGF gene therapy | uniQure/Voyager | Discovery | — | Preclinical |

Development Challenges

| Challenge | Solution | Companies Working |
|-----------|----------|-------------------|
| BBB penetration | AAV-mediated expression, intranasal delivery | uniQure, Voyager |
| Mitogenic risk | FGFR1-selective agonists, engineered variants | Multiple |
| Delivery optimization | Focused ultrasound, convection-enhanced delivery | AskBio, others |
| Sustained expression | Regulated AAV systems, cell-type specificity | All gene therapy companies |

Scientific Foundations

FGF Signaling in AD

FGF signaling is impaired in multiple ways in AD:

Therapeutic Rationale

FGF/FGFR therapy addresses:

• Neurogenesis: FGFR1 activation promotes neural stem cell proliferation
• Synaptic plasticity: FGF2 enhances LTP and memory formation
• Neuronal survival: PI3K/Akt anti-apoptotic signaling
• Metabolic regulation: FGF21 provides metabolic benefits with BBB penetration

Preclinical Evidence

• FGF2 protects hippocampal neurons from amyloid-beta toxicity
• FGFR1 agonists restore neurogenesis in AD mouse models
• FGF21 improves cognitive function in aged animals
• AAV-FGF2 enhances synaptic markers in preclinical models

Competitive Landscape

FGF vs. Alternative Neurotrophin Approaches

| Approach | Advantages | Disadvantages | Companies |
|----------|------------|--------------|-----------|
| FGF/FGFR | Multiple pathways, neurogenesis | BBB penetration, mitogenic concerns | Kyowa Kirin, uniQure |
| BDNF | Synaptic plasticity | Limited CNS penetration | PharmaEssentia |
| GDNF | Strong neurotrophic effects | Delivery challenges | uniQure, Roche |
| HGF/MET | Neuroprotection | Novel mechanism | Athira |
| Small molecule | Oral delivery | Novel target risk | BMS, Merck |

Investment Landscape

Recent Funding

| Company | Round | Amount | Year |
|---------|-------|--------|------|
| uniQure | Public | $140M | 2024 |
| Voyager | Series C | $100M | 2024 |
| Athira | Series C | $85M | 2024 |
| T3D Therapeutics | Series B | $35M | 2023 |

M&A Activity

• AskBio → Pfizer (2021): $2.2B deal
• BMS → Celgene (2019): $74B CNS focus

Future Directions

Emerging Technologies

Research Priorities

• Biomarker development for patient selection
• Delivery optimization for sustained CNS expression
• Safety monitoring for mitogenic concerns
• Efficacy endpoints in clinical trials

Cross-References

• [FGF/FGFR Modulator Therapy](/therapeutics/fgf-fgfr-modulator-therapy)
• [FGF Signaling in Neurodegeneration](/mechanisms/fgf-signaling-neurodegeneration)
• [AD Neurogenesis Companies](/companies/ad-neurogenesis-companies)
• [PD FGF/FGFR Signaling Companies](/companies/pd-fgf-fgfr-therapies)
• [Growth Factor Therapies](/therapeutics/growth-factor-therapies)
• [Neurotrophic Factor Therapies](/therapeutics/neurotrophic-factor-therapies)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving ad-fgf-fgfr-signaling-neurogenesis-companies discovered through SciDEX knowledge graph analysis: